You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Extending WAAVES+: An animal and environment-agnostic, automated USV scoring platform for high-throughput social, behavioral, and neuropharmacological studies
SBC: CORNERSTONE RESEARCH GROUP INC Topic: 101Project SummaryUltrasonic vocalizations (USVs) are known to reflect emotional processing, brain neurochemistry and brain function - key observations in animal model studies. Collecting and processing USV data is time-intensive, manual, and costly. Most importantly, it limits researchers’ ability to employ fully effective, and nuanced experimental designs, and is a barrier to entry for other rese ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Stem Cells for Treating Acute Stroke
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: 999ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel Small Molecule Flavivirus Inhibitors
SBC: VIROGENOMICS, INC. Topic: N/ADESCRIPTION (provided by applicant): We have identified TYT-1 as a novel sultam thiourea inhibitor of West Nile virus (WNV) replication. The compound has a 50% effective concentration (EC50) of 0.7 micromolar and a 50% cytotoxic concentration (CC50) of gt70 micromolar, yielding a therapeutic (selectivity) index of gt100. We have demonstrated that TYT-1 protects animals from the lethality of WNV in ...
STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
A Synthetic Human Cytomegalovirus Vaccine Platform
SBC: TOMEGAVAX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Cuff Electrodes with Soft Wire Electrical Leads
SBC: TDA RESEARCH, INC. Topic: 102Project Summary AbstractDevelopment of a Nerve Cuff Electrode from Soft and Elastomeric Conducting Wires STTR Phase I ApplicationPIBrady ClapsaddleTDA ResearchIncBio electronic interfaces are used in a wide array of applications for recording and providing electrical impulses to treat diseaseOne common interface device for the PNS is the cuff electrodeCurrent cuff electrodes have many failure mode ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.
SBC: BIOMIMETIX JV LLC Topic: 102Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Conversations About Cancer (CAC): A Theatrical Production
SBC: KLEIN BUENDEL, INC. Topic: NCIDESCRIPTION (provided by applicant): Over the past decade, an investigation of how family members talk through cancer on the telephone has resulted in the recent publication of a lengthy volume entitled A Natural History of Family Cancer: Interactional Resources for Managing Illness (NH). Based on the conversations analyzed for this volume, and related research on the psychosocial impacts and con ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity
SBC: INVENUX, LLC Topic: NCCAMDESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health